Incite Corp. and Moffitt Cancer Center this week announced a three-year collaboration agreement, under which Incyle will provide funding for three Moffitt Cancer Center research programs that focus on understanding and developing therapies for specific blood cancers.
“Having access to Incyte’s diverse pipeline of targeted cancer therapies represents a unique and exciting opportunity for Moffitt researchers to expand our efforts to advance medical research in oncology and improve medical care for patients with cancer,” Moffitt's Office of Innovation and Industry Alliances Senior Director and Associate General Counsel Jarett Rieger said. “A huge strength of Moffitt is our ability to form interdisciplinary research teams, and this exciting research alliance, involving numerous faculty members, is a testament to our team science culture.”
The research teams will investigate specific neoplasms, lymphomas and leukemias. The research will use Incyte's small molecule therapeutics as single agents and in combination.
“Incyte and Moffitt are both committed to improving the lives of patients with cancer through the discovery and development of novel medicines," Incyte’s Chief Scientific Officer Reid Huber said. "This research alliance will enable new and important research into multiple blood cancers in a manner that both leverages and extends our current drug discovery efforts. We are pleased to expand our growing network of academic collaborations and join forces with the world class investigators from Moffitt to advance the landscape of cancer treatment.”
Alerts Sign-up